Skip to main content
spacbrain

Altitude Acquisition Corp.

ALTU · Nasdaq

Trust settledVesicor Therapeutics, Inc. · Finished

NO ACTION REQUIRED

Nothing left to do

The purchase completed and the shares became shares in the company it bought. There is no deadline left to miss.

Cash at settlement

no closing figure

No cash-per-share figure was filed for this vehicle before it finished.

Last close

no quote on file

Daily close

Nothing left to claim

this vehicle finished

There is nothing to hand back: holders who wanted cash elected it at the vote, and the rest became shares in the buyer.

Read what happened to the cash

The floor

Trust settled

This SPAC has finished — its trust was paid out or used to close the deal, so there is nothing left to redeem

Read the reasoning behind this verdict

No price history on file yet — daily closes accumulate from the market data feed.

Trust settled · There is no line to draw here. This vehicle has finished: the cash was paid back or spent closing the deal, so the last filed figure describes an account that no longer exists and would be a floor under nothing.

SpacBrain’s read

Trust settled

The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

In plain terms

What it is
A SPAC from Founders Altitude Acquisition Holdco LLC, listed on Nasdaq in December 2020.
What it's doing now
It agreed to buy Vesicor Therapeutics, Inc., a microvesicle-based cancer therapeutics development company. The deal valued that business at about $70M. That purchase completed, and it stopped being a SPAC — the shares became shares in the business it bought.
What you should know
This SPAC has finished. The purchase completed, and the shares became shares in the company it bought — anyone who wanted the cash instead asked for it at the vote, so there is no cash left here to claim and no deadline left to miss.

At a glance

Where it stands
Closed (deSPAC)
The business it bought
Vesicor Therapeutics, Inc.
Industry
Health Care — microvesicle-based cancer therapeutics development
Deal value
$70M
Price vs cash at settlement
no live price on file
Cash in trust when it settled
not yet extracted into a snapshot — the filings below may state it
the last trust total filed while this was still a SPAC — the account has since been paid out or used to close the deal
IPO
10 December 2020
size not on file · 100.0% of each $10 unit into trust
Headquarters
1240 WEST WESLEY ROAD, ATLANTA, GA, 30327
registered in Delaware
Lead underwriter
not extracted from the prospectus yet
Key officers
Hosseinion Warren (Director) · Teplis Gary (Chief Executive Officer) · BNP PARIBAS ARBITRAGE, SA
Listed securities
ALTU common
Cash held per sharenot filed for this window

This vehicle has finished, so there is no window to file a cash-per-share figure for and none will follow. No estimate is shown in its place.

Shares already handed backthe filing does not state a pre-event share count

At the 7 April 2023 event.

0001193125-23-145104opens on sec.gov in a new tab

Next date that mattersno dated event on file

Nothing dated is on file. That is an absence in the record, not a statement that nothing is coming.

Yield to redemption

Nothing left to redeem — no yield to compute.

This SPAC has finished — its trust was paid back or used to close the deal, so there is nothing left to redeem and no yield to compute. A yield to redemption is a claim that you can hand these shares back for the trust cash. That account is closed, so this page will not print a number here.

What happened to the cash

The reasoning behind the verdict above, in the order the filings establish it.

  1. The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

What has happened, and what is coming

4 dated milestones

Every dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.

  1. 10 June 2022Shares handed backpassed0001193125-23-145104opens on sec.gov in a new tab

    redemption rate not stated in the filing

  2. 6 October 2022Shares handed backpassed0001193125-23-145104opens on sec.gov in a new tab

    redemption rate not stated in the filing

  3. 7 April 2023Shares handed backpassed0001193125-23-145104opens on sec.gov in a new tab

    redemption rate not stated in the filing

Show the earlier 1 milestone
  1. 10 December 2020IPOpassed

    IPO size not on file

The deal

terms as filed

What it is buying, on what terms, and how much of the combined company new shares take from you.

  • Vesicor Therapeutics, Inc.$70M
    closedDeveloping a cancer therapeuticSEC primary

    What Vesicor Therapeutics, Inc. does — read from vesicor.com on 27 August 2026

    Vesicor Therapeutics, Inc. is a company focused on transforming oncology through precision-engineered microvesicles that deliver p53 mRNA directly to cancer cells using a non-viral, immune-silent delivery platform.

    OncologyGene Therapy

Who has already taken their money back

3 filed events

Each time shareholders were offered their cash back, some took it. Heavy cash-outs drain the account and shrink the number of shares left — whatever remains has to carry the deal.

Worst single event

—

no filing states a pre-event share count

Shares redeemed, all events

28.67M

across every filed redemption event

Every figure below is stated in the linked filing; nothing here is estimated.

Show the other 2 cash-out events

The score

deterministic, from filed fields

ALTU is not in the scored universe, so no score is shown. A withheld score is a fact about the record, not a verdict about the company.

Asymmetric return scoreNeither a price nor a cash-per-share figure is on file for this vehicle, and the score is a ratio between the two. Nothing is estimated to fill the gap.

The score is only published for names that carry both a price and a filed cash-per-share figure — 292 of the tracked fleet today. The rest keep an empty dial rather than a modelled one, and fill in by themselves as the fields land.

See the names that are scored, and how

The company

from SEC filings
Read the full profile

Altitude Acquisition Corp. (Nasdaq: ALTU) was a blank-check company whose common stock traded under the ticker ALTU on the Nasdaq Stock Market. The company priced its initial public offering on December 10, 2020, under SEC file number 333-249071, with shares registered for cash on Form S-1 (accession 0001193125-20-254700) and a corresponding 424B4 prospectus (accession 0001193125-20-314985). The registrant self-described as a blank check company in that prospectus and was classified under SEC SIC industry code 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Altitude Acquisition Corp. completed a business combination and no longer files as a public vehicle, as established by a Form 425 filing dated March 1, 2024 (accession 0001193125-24-054627) describing a merger in which the company became a wholly-owned subsidiary of a public company that changed its name to Vesicor Therapeutics, Inc. The common ticker ALTU appears on the cover page of a Form 8-K filed February 29, 2024 (accession 0001193125-24-053687).

Material findings

from the full read of every filing

Every document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.

  • DEF 14A13 November 20230001193125-23-276215opens on sec.gov in a new tab

    Redemption at $10.34 beats the $10.15 market price by nineteen cents, so tendering was worth more than selling. The governance point is stark and stated outright: insiders hold enough shares to pass the extension unaided, so the vote is a formality and public holders' only real decision is whether to redeem. Three months of extension authority delegated to the board removes the recurring redemption windows that would otherwise follow.

  • PREM14A14 August 20230001193125-23-212531opens on sec.gov in a new tab

    The 48,000,000-share pool is subject to adjustment for Picard's cash and indebtedness at closing, and up to 6,500,000 further Earnout Warrants sit in escrow, released only if the VWAP of New Picard common stock exceeds $12.50 for any 20 trading days within any 30 trading day period in the five years after closing. Picard's preferred stock and convertible notes convert into common before the first merger, so they share in that pool. The Sponsor has agreed to vote in favour and not to redeem or transfer its Founder Shares, and 100,000 shares and 30,000 warrants go to Altitude service providers.

  • DEF 14A23 March 20230001193125-23-077949opens on sec.gov in a new tab

    Insiders holding enough votes to carry every proposal unaided means the meeting is a formality and the only real decision for ALTU holders is whether to redeem at roughly $10.07, a cent above the market price. Deleting both net tangible asset limitations removes the floor that would otherwise block a deal after heavy redemption, and early founder share conversion adds low-basis stock to the Class A count. Eight months of monthly extensions are granted at once.

  • DEF 14A16 September 20220001193125-22-245965opens on sec.gov in a new tab

    Redeeming at roughly $10.05 was worth eight cents more than selling at $9.97, with settlement certainty. Retaining the $5,000,001 net tangible asset condition means mass redemption simply ends the vehicle and returns cash, which limits the downside of staying. That founder shares alone can carry the Adjournment Proposal shows ALTU public holders cannot block a postponement, only decide whether to redeem.

  • DEF 14A10 May 20220001193125-22-145885opens on sec.gov in a new tab

    The target is unnamed and the company concedes it has neither completed due diligence nor negotiated a definitive agreement, so holders are being asked to fund an extension for a transaction that does not yet exist on paper. Retaining the $5,000,001 net tangible asset condition means heavy redemptions abort the extension and return trust value, which protects those who want out. At about $10.00 per share the redemption returns deposited value, so the decision is whether the option on an undocumented deal is worth the wait.

Filings

live EDGAR feed

Everything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.

Show the other 10 filings

The record

The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.

Show the reference detail

Unit structure

Cash in trust at IPO$10.00

Unit: U = S + W/2 · 100.0% of the $10 unit

from 424B4 0001193125-20-314985

Trading & liquidity

Average daily volume (20d)no volume reported on the bars we hold
Average daily $ volumeneeds both volume and a live price
Range over the bars heldnot enough price history
Total cash in trustthe trust total is not in the last XBRL stamp

Company profile

Industry (SIC)Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
Registered inDelaware
Exchange · CIKNasdaq · 0001822366

All filings on EDGARopens on sec.gov in a new tab

Directors & officers

Institutional holders

from SC 13G/13D

Funds that have declared a stake above 5%. Heavy ownership by arbitrage funds usually means heavy cash-outs at the next vote.

Show the declared stakes

7 filers with a stake on file · 0 re-affirmed in the last 12 months. A stake with no amendment since is the filer’s last word on it, not proof it is still held — and percentages filed in different years are percentages of different floats, because this vehicle’s share count collapses at every redemption.

One line per filer, not per reporting person: a joint schedule names the management company, its funds and often the individual who controls them, and all of them report the same shares. Click a name for that filer’s whole footprint across every SPAC it has declared a stake in.

Sources on file

harvested pages, kept in full

Every public page we have read about this company, stored in full so a source can never go missing.

Show the sources

37 full SEC filing texts archived — searchable, never lost.

In plain English

tap a term to open it

Every piece of jargon this page could have used, and what it actually means.

Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected

A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.

Redemption deadlinethe last day to hand shares back for cash

Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.

Broker action datethe day your broker needs the instruction — earlier than the official date

Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.

Cash in trust / trust per sharethe cash the company is holding for each public share

Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.

Trust discountbuying below the cash held for you

Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.

Dilutionhow much of the company new shares take from you

Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.

Pro-forma equitywhat the company is valued at once the deal closes

The combined company's equity value assuming the announced terms and the redemptions that have actually happened.

ARShow much upside you get per unit of downside

SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.

De-SPACthe day the SPAC becomes the real company

The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.

Outside datethe contractual long-stop for closing the deal

A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.

Accession numberthe SEC's unique id for one filing

Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.

Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since

A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.

Ask the brain

from its filings
Data provenance & audit trail5 internal entries

Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.

ALTU — company record
UNIVERSE-IPO-INDEX2026-08-17

admitted from EDGAR's QUARTERLY FORM INDEX, walked without any SIC filter. The SIC 6770 census could not reach this registrant: EDGAR reassigns a shell's SIC the day it stops being one, and this CIK now files under 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). The screen found it by filing SHAPE instead — S-1 2020-09-25 → 8-A12B 2020-12-07 → 424B4 2020-12-10 — which nothing rewrites. Admission rule: src/lib/universe-admit.ts. SIC 3842 + self-described blank check in 424B4 0001193125-20-314985; 424B 0001193125-20-314985 priced 2020-12-10 under S-1 0001193125-20-254700 (file 333-249071, an offering for cash); common ticker ALTU off 8-K 0001193125-24-053687 (2024-02-29); lifecycle EXITED. The pricing prospectus was filed under SEC file number 333-249071, which belongs to S-1 0001193125-20-254700 (2020-09-25) — a registration of shares sold for CASH, which is what makes it an IPO rather than merger consideration. Blank-check status from the registrant's own first-person sentence in that prospectus (EDGAR full-text search, 424B4 2020-12-10). Ending PROVEN, not inferred: CLOSED per 425 0001193125-24-054627 (2024-03-01) — ction pursuant to which (i) Merger Sub will merge with and into the Company (the “ Merger ”), after which the Company will be the surviving company (the “ Surviving Corporation ”) and a wholly-owned subsidiary of PubCo, and (ii) PubCo shall change its name to “Vesicor Therapeutics, Inc.”; E. The parties hereto intend that, for U.S. federal income tax purposes, the Mer. ipoSizeM and deadline left NULL: gross-proceeds prose conflates the over-allotment with the offering, and a charter deadline belonging to a vehicle that has ended is a date nobody can act on. ipoDate is the 424B pricing date.

SPONSOR-ID2026-08-14

sponsor "Founders Altitude Acquisition Holdco LLC" sourced from prospectus definition (10-K/A) acc 0001193125-21-178653.

Deal — Vesicor Therapeutics, Inc.
DEAL-TARGET2024-03-01

AI-extracted target (z-ai/glm-5.2, conf 1)

BACKFILL2026-08-26

target recovered for a completed de-SPAC; no agreement-naming filing on file, so announcedAt is NULL rather than guessed

PROFILE-STUB2026-08-27

entity created from the filed target name; no About paragraph on file, so every other field awaits a sourced read

Also listed inSPACs with warrants
Back to the screenerVault note